tation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
, 11717 or by calling toll-free (866) 803-9204.
Pharmacyclics, Inc., headquartered in Sunnyvale, California, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its corporate mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs; and to identify promising product candidates based on scientific and administrational development expertise, develop our product candidates in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs toward viable commercialization.
Pharmacyclics, Inc. Contacts:
Joshua T. Brumm
Executive Vice President, Finance
Senior Vice President of Investor Relations
Page: 1 2 Related medicine technology :1
. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes2
. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 20123
. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies4
. Misonix Announces New Distribution Agreement For Panama5
. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park6
. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center7
. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter8
. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability9
. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors10
. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study11
. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast